Our Team

Dr. David G. Boyd, PharmD is an accomplished clinical development expert with over 30 years of experience specializing in oncology, neurology, hematology, and orphan indications. His career spans extensive roles in protocol development, regulatory affairs, medical operations, and clinical research oversight, with particular expertise in solid tumor cancers and hematologic malignancies.
 
Dr. Boyd has served as an independent consultant at Oceania Clinical Group since 2012, where he has contributed to the development of innovative immuno-oncology biologics and supported regulatory submissions for Phase III cancer therapeutics. His work includes key contributions to CAR-T programs, BLA submissions for leukemia treatments, and global oncology trial management. Previously, Dr. Boyd held leadership positions at Osmotica Pharmaceuticals, Solvay Pharmaceuticals, and Amgen, where he directed clinical strategies and successfully advanced new treatments for neurological and gastrointestinal diseases, among others.
 
Throughout his career, Dr. Boyd has been responsible for overseeing clinical trials, interacting with regulatory agencies, and authoring numerous publications, abstracts, and presentations. His dedication to clinical excellence has resulted in significant advancements in oncology, hepatitis C, cystic fibrosis, and other critical areas of medicine.
 
Dr. Boyd earned his PharmD from the University of Nebraska and has a rich academic background in pharmaceutical sciences and physiology. He continues to offer consultancy services, focusing on clinical and regulatory strategy for novel therapeutics.